David I Smith received his Ph.D. In 1978 from the University of Wisconsin in Madison in Biochemistry. After postdoctoral training at the Albert Einstein College of Medicine and the University of California, Irvine, he got his first faculty position at Wayne State University. Since 1996 he has been a full Professor in the Department of Laboratory Medicine and Pathology at the Mayo Clinic. He is also the Chairman of the Technology Assessment Group for the Mayo Clinic Center for Individualized Medicine. His research focuses on genomic instability and the role that the common fragile sites play in cancer development. His group is also studying the different ways that human papilloma virus is involved in the development of different cancers. They utilize the powerful tool of next generation sequencing the study these problems.
Philippe METELLUS is Professor of Neurosurgery at the Clairval Hospital Center in Marseille, France. He is specialized in brain tumors and is the actual leader of the Glioma and the Brain Metastases program in France. Besides his clinical activity, he is running translational and basic science research program in the INSERM UMR 911 unit. His clinical and research activities are focused on Gliomas and Brain Metastases. A surgical research program on gliomas located in eloquent areas including awake craniotomies with electroencephalographic recordings has been developed with his neurological team in 2011. Also, a translational research program on Gliomas and Brain Metastases biology is conducted with the oncological transfer laboratory at the Aix-Marseille University. These programs involve a multi-disciplinary brain tumor consortium including, Neurologists, Neuro-Oncologists, Medical-Oncologists, Radiation-Oncologists, Neuro-Radiologists, Pathologists and the translational oncology university platform. Since 2011, Prof. Metellus organizes the Annual Brain Metastases Research and Emerging Therapies Conference in Marseille.
Young Rok, Do is awarded PhD in Internal Medicine from Keimyung University, Taegu, Korea in the 2004. He has extended his valuable service as an Associate Professor in Keimyung University for 5 years and has been a recipient of many award and grants. Currently, he is working as an Professor at Keimyung University School of Medicine. He serves as a member of various associations- Korean Medical Association, Korean Cancer Association, American Society of Clinical Oncology and APBMT. His clinical and research interest focusing on Acute Leukemia, Including Hematopoietic Stem Cell Transplantation and CML, Clinical Trial including TFR. His research interests reflect in his wide range of publications in various national and international journals.
Young Rok, Do (Research Area)
CML Clinical Trial including TFR, NHL Including New Drug Clinical Trial, Multiple Myeloma Including New Drug Clinical Trial, Acute Leukemia Including Hematopoietic Stem Cell Transplantation and Gauchers Disease
Dr. Qing Kay Li is an associate professor of department of pathology at the Johns Hopkins University School of Medicine. She has the American Board of Pathology certification in surgical and cytopathology. Her clinical expertise include surgical pathology, cytopathology, and oncological pathology. Dr. Li is also a PI at the Johns Hopkins Biomarker Discovery Center. Her research interests is focusing on the application of advanced molecular techniques to the field of cancer biology, particularly in the field of early detection of lung and prostate cancer. Dr. Li serves as editorial board members for several journals; committee members of the American Society of Cytopathology, Papanicolaou Society of Cytopathology, NIH/NCI lung cancer, and kidney cancer working group; study sections of government agents and private organizations. She has more than 120 publications, including several book chapters and books. She has served as a keynote speaker at many national and international meetings.
Dr. Sebastian is the Director of NCI funded Research Histology Pathology & Imaging Core in MD Anderson Cancer Center (MDACC) which supports both translational research and drug development programs for multiple institutions in the country. He is an Associate Prof in the Department of Epigenetics and Molecular Carcinogenesis of MDACC. He is a board certified pathologist and toxicologist with more than 20 years of experience in both academia and drug industry. After completing his PhD and residency in pathology from University of Kentucky, Dr. Sebastian held faculty positions in in University of Georgia, Cornell University and Columbia University, where he was the Chief of Comparative Pathology. After working 6 years in biotech industry, in August 2016, Sebastian was recruited to MDACC. Dr. Sebastian was/is a Co-PI of multiple federally funded grants from NIH and BARDA. His primary focus is translational research in cancer with special interest in cancer drug discovery and development, safety evaluation and regulatory approval.
Dr. Wang received his M.D. from Tongji Medical College, Huazhong University of Science & Technology in 1987 and his Ph.D. in Biochemistry & Molecular Biology from the University of Texas (UT) Graduate School of Biomedical Sciences (Houston, TX) in 1999. He did his residency at the UT Medical School (Houston) from 1999 to 2003 and his fellowship in Selective Surgical Pathology at UT MD Anderson Cancer Center (MDACC) from 2003 to 2004. In July 2004, Dr. Wang joined the Department of Pathology at MDACC as an assistant professor specialized in gastrointestinal, liver and pancreatic pathology. He is currently a tenured professor of pathology with joint appointment as a professor in the Department of Translational Molecular Pathology (MDACC) and at UT Graduate School of Biomedical Sciences in Houston. Dr. Wang is the co-director of pancreatic cancer tumor bank and serves as the Scientific Advisory Board member for the Sheikh Ahmed Center for Pancreatic Cancer Research at UTMDACC. Dr. Wang is well recognized in the field of GI and pancreaticobiliary pathology and in clinical/translational research of pancreatic cancer. His major research interests are focused on tumor biology, animal models, tumor markers for early detection, prognosis, and treatment for pancreatic cancer. Dr. Wang has served as principle investigator (PI), pathology core leaders, co-PI, or co-investigator for more than 35 research grants including NIH/NCI Specialized Program of Research Excellence (SPORE) on pancreatic cancer, P01s, U01, R01s, K08, R21s and the Moonshot Program on pancreatic cancer at MDACC. Dr. Wang has authored more than 200 peer-reviewed publications in prestigious journals including Nature, Cell, Nature Communications, Cancer Cell, Journal of Clinical Oncology, Proceedings of National Academy of Sciences USA, Gastroenterology, Journal of Clinical Investigation etc., 12 invited review articles and 9 book chapters. He is serving as the editors for 12 prestigious scientific journals and as an ad hoc reviewer for 34 journals. He received many awards for his research, including the Career Development Award from the American Association for Cancer Research. As an expert in GI pathology, he was selected to serve on the American Joint Committee on Cancer (AJCC) Foregut Task Force for the 7th edition of the AJCC Cancer Staging Manual. Dr. Wang was the President of the Chinese American Pathologists Association (CAPA) 2016-2017, which is the largest organization in North America for the pathologists who cherish Chinese culture. Under his strong leadership, CAPA membership grew 42% from 510 to 725 in one year. Dr. Wang is a member of the Publications Committee and a member of the Ramzi S. Cotran Young Investigator Award Committee of the United States and Canadian Academy of Pathology (USCAP).
Huamin Wang(Research Area)
Clinical/translational research of pancreatic cancer
Dr. Wa Xian received her Bachelorâ€™s degree in Biochemistry from Nankai University in China and Ph.D. degree in Molecular Genetics at the University of Texas Graduate School of Biomedical Sciences in Houston, focusing on master regulator genes of cell proliferation and lineage specification during early neural development. The support of a DOD breast cancer fellowship enabled Dr. Xianâ€™s postdoctoral studies with Prof. Jeffrey Rosen at the Baylor College of Medicine. There she used a combination of ligand-induced dimerization strategies and a mammary epithelial 3D culture system to address the role of fibroblast receptor tyrosine kinase signaling in the evolution of breast cancer. In 2008, Dr. Xian moved to Harvard Medical School under the direction of Prof. Christopher Crum, Director of Womenâ€™s and Perinatal Pathology at the Brigham and Womenâ€™s Hospital to study the origin and evolution of ovarian cancer. Dr. Xian continues to work very closely with Prof. Crum on the origins and chemotherapy resistance problem in high-grade ovarian cancer. In 2009, Dr. Xian was appointed Principal Investigator at the Institute of Medical Biology of the Agency for Science, Technology, and Research in Singapore, where she jointly oversaw a highly interactive group of postdoctoral fellows, graduate students, and research assistants with Prof Frank McKeon of the Genome Institute of Singapore devoted to the cloning of stem cells of regenerative tissues and using advanced technologies to understand the genetics of their self-renewal, commitment, and differentiation. In 2013, Dr. Xian returned to the US and initiated multiple projects related to inflammatory diseases and cancer with colleagues at the University of Connecticut Health Center. In 2015, Dr. Xian received the Rising Stars Award from the Cancer Prevention & Research Institute of Texas (CPRIT) and was recruited to the Institute of Molecular Medicine at the University of Texas Health Science Center in Houston.
Kenji Suzuki, Ph.D. (by Published Work; Nagoya University) worked at Hitachi Medical Corporation, Japan, Aichi Prefectural University, Japan, as a faculty member, and in Department of Radiology, University of Chicago, as Assistant Professor. In 2014, he joined Department of Electric and Computer Engineering and Medical Imaging Research Center, Illinois Institute of Technology, as Associate Professor. In 2017, he was jointly appointed in World Research Hub Initiative at Tokyo Institute of Technology as Full Professor (Specially Appointed). He published more than 320 papers (including 110 peer-reviewed journal papers). His papers were cited more than 8,000 times by other researchers. He has an h-index of 41. He is inventor on 30 patents (including 13 granted patents), which were licensed to several companies and commercialized. He published 10 books and 22 book chapters, and edited 13 journal special issues. He was awarded/co-awarded more than 25 grants as PI including NIH R01 and ACS. He served as the Editor of a number of leading international journals, including Pattern Recognition and Medical Physics. He served as a referee for 80 international journals, an organizer of 30 international conferences, and a program committee member of 150 international conferences. He received 25 awards, including 3 RSNA Certificate of Merit Awards, IEEE Outstanding Member Award, Cancer Research Foundation Young Investigator Award, Kurt Rossmann Award for Excellence in Teaching from Univ of Chicago, IEICE 2014 Best Journal Paper Award, EANM Most Cited Journal Paper Award 2016, and 2017 Albert Nelson Marquis Lifetime Achievement Award.
Kenji Suzuki(Research Area)
Machine learning, deep learning, computer-aided diagnosis, medical image processing, medical image analysis, and artificial intelligence.
Dimitrios H. Roukos, MD, PhD, is the founding director of Centre for Biosystems and Genome Network Medicine in the Ioannina University, School of Medicine. Assessing the current and future unmet needs of traditional clinical research and single-gene linear transcription-based targeted therapy, he has moved to clinical cancer genome sequencing, regulatory molecular networks and nonlinear transcription. Comprehensive intrapatient landscapes of genomic alterations represent his current research focus. With over 232 papers, including 80 on next-generation sequencing and 32 on precision medicine-oncology, 8,130 citations, h-index of 70, reviewer for high impact journals, editorial board member in more then 25 high-impact journal, lecturer and organizing committee member for international conferences, he is an internationally recognized leading expert of precision cancer genome medicine.
Dimitrios H. Roukos(Research Area)
clinical cancer genome sequencing, regulatory molecular networks and nonlinear transcription